1. Home
  2. CAC vs ANL Comparison

CAC vs ANL Comparison

Compare CAC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$50.13

Market Cap

857.1M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$11.94

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
ANL
Founded
1875
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
857.1M
731.6M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
CAC
ANL
Price
$50.13
$11.94
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$47.00
$20.00
AVG Volume (30 Days)
77.4K
182.3K
Earning Date
04-28-2026
04-10-2026
Dividend Yield
3.51%
N/A
EPS Growth
6.08
N/A
EPS
1.29
N/A
Revenue
$41,739,000.00
N/A
Revenue This Year
$19.15
$36.02
Revenue Next Year
$6.05
N/A
P/E Ratio
$38.62
N/A
Revenue Growth
16.96
N/A
52 Week Low
$35.00
$0.88
52 Week High
$53.71
$17.25

Technical Indicators

Market Signals
Indicator
CAC
ANL
Relative Strength Index (RSI) 58.30 47.32
Support Level $47.12 $11.86
Resistance Level $51.57 $12.09
Average True Range (ATR) 1.07 1.34
MACD 0.21 -0.25
Stochastic Oscillator 77.44 29.71

Price Performance

Historical Comparison
CAC
ANL

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: